Elevated serum anti-12 and anti-OmpW antibody levels in children with IBD

Inflammatory Bowel Diseases

Volumn 12, Issue 5, 2006, Pages 389-394

  Iltanen, Sari ^a,b   Tervo, Laura ^a   Halttunen, Tuula ^a   Wei, Bo ^c   Braun, Jonathan ^c   Rantala, Immo ^b   Honkanen, Teemu ^b   Kronenberg, Mitchell ^d   Cheroutre, Hilde ^d   Turovskaya, Olga ^d   Autio, Ville ^a   Ashorn, Merja ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Bacterial antigens; Children; I2; Inflammatory bowel disease; OmpW; Serological response

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN W; PERINUCLEAR NEUTROPHIL CYTOPLASMIC ANTIBODY; PSEUDOMONAS FLUORESCENS ASSOCIATED SEQUENCE I2; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ARTICLE; BACTEROIDES; BACTEROIDES CACCAE; CHILD; CONTROLLED STUDY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PATIENT REFERRAL; PRIORITY JOURNAL; PSEUDOMONAS FLUORESCENS; SACCHAROMYCES CEREVISIAE; SERUM; ULCERATIVE COLITIS; UNITED STATES;

ADOLESCENT; ANTIBODIES; BACTERIAL OUTER MEMBRANE PROTEINS; CHILD; CHILD, PRESCHOOL; HUMANS; INFLAMMATORY BOWEL DISEASES; SUPERANTIGENS;

EID: 33646773971     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000218765.84087.42     Document Type: Article

References (41)

1. Hugot J-P, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-606.
2. Hamper J, Cuthbert A, Croucher PJP, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357:1925-1928.
3. Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet. 1996;347:1212-1217.
4. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
5. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253-261.
6. Powrie F, Leach MW, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993;5:1461-1471.
7. Aranda R, Sydora BC, McAllister PL, et al. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol. 1997;158:3464-3473.
8. De Winter H, Cheroutre H, Kronenberg M. Mucosal immunity and inflammation. II: the yin and yang of T cells in intestinal inflammation: pathogenic and protective roles in a mouse colitis model. Am J Physiol. 1999;276:G1317-G1321.
9. Strober W, Ludviksson BR, Fuss IJ. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease. Ann Intern Med. 1998;128:848-856.
10. Bhan AK, Mizoguchi E, Smith RN, et al. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev. 1999;169:195-207.
11. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 2000; 119:23-31.
12. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123:689-699.
13. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376-2384.
14. Garcia-Lafuente A, Antolin M, Guarner F, et al. Incrimination of anaerobic bacteria in the induction of experimental colitis. Am J Physiol. 1997;272:G10-G15.
15. Wei B, Dalwadi H, Gordon LK, et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect Immun. 2001;69:6044-6054.
16. McKenzie H, Main J, Pennington CR, et al. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut. 1990;31:536-538.
17. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-496.
18. Dubinsky MC, Ofman JJ, Urman M, et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001;96:758-765.
19. Bartunkova J, Kolarova I, Sediva A, et al. Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cervisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel disease. Clin Immunol. 2002;102:162-168.
20. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235-2241.
21. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306.
22. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128:2020-2028.
23. Evans CM, Beattie RM, Walker-Smith JA. Inflammatory bowel disease in childhood.In: Allan RN, Rhodes JM, Hanauer SB, eds. Inflammatory Bowel Diseases. 3rd ed. New York: Churchill Livingstone; 1997:647-670.
24. Dixon FM, Genta RM, Yardley JH, et al. Classification and grading of gastritis: the updated Sydney System: International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.
25. Van der Woude FJ, Lobatto S, Permin H, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425-429.
26. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS. 1989;6(Suppl):12-13.
27. Wiik A. Granulocyte-specific antinuclear antibodies. Allergy. 1980;35:263-289.
28. Cohavy O, Harth G, Horwitz M, et al. Identification of a novel mycobacterial histone H homologue (HupB) as an antigenic target of pANCA monoclonal antibody andserum immunoglobulin A from patients with Crohn's disease. Infect Immun. 1999;67:6510-6517.
29. Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000;68:1542-1548.
30. Wei B, Huang T, Dalwadi H, et al. Pseudomonas fluorescens encodesthe Crohn's disease-associated 12 sequence and T-cell superantigen. Infect Immunol. 2002;70:6567-6575.
31. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685-693.
32. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cutoplasmic shuttling of PPAR-gamma and REIA. Nat Immunol. 2004;5:104-112.
33. Mylonaki M, Rayment NB, Rampton DS, et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:481-487.
34. Rump JA, Schölmerich J, Gross V, et al. A new type of perinuclear antineutrophil cytoplasmic antibody (pANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology . 1990;181:406-413.
35. Saxon A, Shanahan F, Landers CJ, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202-210.
36. Rutgeerts P, Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology. 1998;115:1006-1022.
37. Halme L, Turunen U, Helio T, et al. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol. 2002;37:692-698.
38. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235-2241.
39. Main J, McKenzie H, Yeaman GR. Antibody to Saccharomyces cerevisiae (baker's yeast) in patients with Crohn disease. BMJ. 1988;297:1105-1106.
40. Giaffer MH, Clark A, Holdsworth CD. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut. 1992;33:1071-1075.
41. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.